Skip to content

Study · Case report or series · n = 1 · 2025

3 results

Failure of GLP-1 Agonist Therapy to Improve Weight in a 3-Year-Old Patient With Tumor-Related Obesity.

Petlansky R, Graber E

Case reports in pediatrics20 Nov 2025Cited by 1 (Europe PMC)

PMID41323567 (opens in a new tab)PMCIDPMC12659972 (opens in a new tab)DOI10.1155/crpe/1707315 (opens in a new tab)PepBankPUB-41323567
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

A 19-month-old female patient presented due to rapid weight gain starting at age 5 months. Due to continued abnormal weight gain after 1 year of age, an MRI of the brain was performed, revealing a 5.5 × 2.6 × 2.3 cm mass centered within the medulla oblongata with extension to the C3 vertebral body. Biopsy confirmed a diagnosis of ganglioglioma. A trial of topiramate was attempted, but there was no improvement in weight gain after 2 months. The patient started on 0.3 mg liraglutide daily, and the dose was titrated up to 3 mg daily over 3 months. The patient did not experience abdominal pain, nausea, vomiting, or diarrhea. Weight continued to increase at a drastic rate, and increased appetite persisted. Liraglutide was discontinued. Liraglutide may be safe for use in children as young as age 3 years. However, its effect on weight loss in cases of hypothalamic obesity may be limited. The medulla oblongata contains GLP-1 receptors and is involved in the suppression of food intake. In the presented case, lack of response to treatment was likely due to medullary damage from the tumor. Further research about the etiology of neurogenic causes of obesity is needed so targeted therapies may be developed.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a young child with tumor-related obesity, weight kept rising on liraglutide and no weight loss occurred.

    In plain wordsIn one young child with a brain tumor and obesity, liraglutide did not stop weight gain.

    Peptide
    Liraglutide
    Outcome
    No significant changeBody weight on liraglutide
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.3 mg daily, titrated up to 3 mg daily over 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Weight continued to increase at a drastic rate
    2 context sentences
    Summary · context
    A 19-month-old female patient presented due to rapid weight gain starting at age 5 months.
    Summary · context
    The patient started on 0.3 mg liraglutide daily, and the dose was titrated up to 3 mg daily over 3 months.
  2. 02HumanCase report or seriesEfficacy outcome

    In a young child with tumor-related obesity, increased appetite persisted during liraglutide treatment.

    In plain wordsIn one young child with a brain tumor and obesity, a high appetite continued during liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    No significant changeAppetite on liraglutide
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    0.3 mg daily, titrated up to 3 mg daily over 3 monthsAs given in this study (human).

    Source sentences

    Summary
    increased appetite persisted.
    2 context sentences
    Summary · context
    A 19-month-old female patient presented due to rapid weight gain starting at age 5 months.
    Summary · context
    The patient started on 0.3 mg liraglutide daily, and the dose was titrated up to 3 mg daily over 3 months.
  3. 03HumanCase report or seriesSafety outcome

    In a young child with tumor-related obesity, no abdominal pain, nausea, vomiting or diarrhea occurred on liraglutide.

    In plain wordsIn one young child, liraglutide caused no stomach pain, nausea, vomiting or diarrhea.

    Peptide
    Liraglutide
    Outcome
    No significant changeGastrointestinal adverse events
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.3 mg daily, titrated up to 3 mg daily over 3 monthsAs given in this study (human).

    Source sentences

    Summary
    The patient did not experience abdominal pain, nausea, vomiting, or diarrhea.
    2 context sentences
    Summary · context
    A 19-month-old female patient presented due to rapid weight gain starting at age 5 months.
    Summary · context
    The patient started on 0.3 mg liraglutide daily, and the dose was titrated up to 3 mg daily over 3 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.